Sorry, but you do not have permission to view this content.
Topic Archives:
The ERISA Industry Committee Calls on Congress to Close Loophole and Deem PBMs as a “Fiduciary” under ERISA
Releases new issue brief detailing how reform would require PBMs to act in the best interest of patients and help keep health insurance costs low
ERIC Health Care Highlights: Patient Congressional Briefing; MHP Final Rule; and More!
Sorry, but you do not have permission to view this content.
ERIC Urging California Governor to Veto Problematic PBM Legislation SB 966 – Opportunity for Member Company Sign-On
Sorry, but you do not have permission to view this content.
Leading Healthcare Stakeholders Respond to Administration Change to Mental Health Parity Act
Washington, D.C., September 9, 2024 – AHIP, the Association of Behavioral Health and Wellness (ABHW), the Blue Cross Blue Shield Association (BCBSA), and The ERISA Industry Committee (ERIC) react to the Tri-Departments’ final mental health and substance use disorder parity rule released today.
ERIC Statement on Release of Mental Health Parity Act
Today, The ERISA Industry Committee (ERIC) released the following statement on the Biden Administration’s changes to mental health and substance use disorder parity regulations under the Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) and the Consolidated Appropriations Act of 2021 (CAA). The statement is attributable to Melissa Bartlett, Senior Vice President of Health Policy for ERIC.
ERIC Health Care Highlights: Advocacy for E-Delivery; DOL EAC Statement; and More
Sorry, but you do not have permission to view this content.
ERIC Health Care Highlights: FDA Interchangeability Comments; Education and Workforce Letter; and More
Sorry, but you do not have permission to view this content.
The ERISA Industry Committee Applauds FDA Efforts to Make Biosimilars More Accessible
Washington, D.C., August 20, 2024 – The ERISA Industry Committee (ERIC) today praised draft guidance (Guidance) by the U.S. Food and Drug Administration (FDA) that will help increase competition in the prescription drug markets, boosting the availability of affordable biosimilar drugs.
ERIC Health Care Highlights: RSVP ERISA 50th Party; Survey Reminders; and More
Sorry, but you do not have permission to view this content.